eu falsified medicines directive developments and ......2016/06/07 · eu falsified medicines...
TRANSCRIPT
EU Falsified Medicines
Directive – developments
and implementations across
Europe
June 2016
Joan Cahill
Pfizer
EFPIA Supply Chain Workgroup – Coding & Serialisation
Disclaimer
This presentation does not necessarily reflect
the views of Pfizer Inc.
E U R O P E A N M E D I C I N E S V E R I F I C A T I O N S Y S T E M 2
Content
E U R O P E A N M E D I C I N E S V E R I F I C A T I O N S Y S T E M 3
Medicines verification in the EU: Overview
European Stakeholder Model → EMVO
Progress to date
EU Falsified Medicines Directive
Safety Features
Authenticity
Pack Identity
Tamper evidence
Good distribution
Wholesalers & Brokers
GDP
Active substances
GMPs for excipients
Internet Sales
Community logo
Feb 9, 2019 2013-Q1 July 2, 2013 2015
Registration API
activities
Jan 2, 2013
Implementation of serialization, verification
system and tamper evident features
Objective Protection of patients from counterfeited
medicines in the legal distribution chain
Content Pan-European system to verify the authenticity
of medicinal products
Cost Paid by Marketing Authorization Holders
E U R O P E A N M E D I C I N E S V E R I F I C A T I O N S Y S T E M 5
2011
Feb 9 2019CompleteImplementation(BE/EL/IT Feb 9 2025)
Feb 9 2016Publication of
Delegated Regulation(EU) 2016/161
July 2011Publication of FMD
(2011/62/EU)
36 Mon.
20192015
Delegated Regulation mandates medicines
verification
E U R O P E A N M E D I C I N E S V E R I F I C A T I O N S Y S T E M 6
Serialization by manufacturer
+
Verification at point of dispense
Safety Features:
Unique Identifier (PC, Lot, Exp, SN)
+
Anti-Tamper Device (ATD)
System set up and governed by
stakeholders under supervision
of competent authorities
Product #: 09876543210982
Batch: A1C2E3G4I5
Expiry: 140531
S/N: 12345AZRQF1234567890
Pan-European System
National verification Systems (NMVS) connected by the
European Hub
E U R O P E A N M E D I C I N E S V E R I F I C A T I O N S Y S T E M 7
National
System
Pharmacy Wholesaler
Pharmaceutical
ManufacturerParallel
Distributor
National
System
National
System
National
System
National
System
National
System
European
Hub
Content
E U R O P E A N M E D I C I N E S V E R I F I C A T I O N S Y S T E M 8
Medicines verification in the EU: Overview
European Stakeholder Model → EMVO
Progress to date
Multiple stakeholders are involved
E U R O P E A N M E D I C I N E S V E R I F I C A T I O N S Y S T E M 9
EU SolutionManufacturer
Parallel distributors
Pharmacy
Distributor/
Wholesaler
Stakeholders work together to deliver a solution across Europe which delivers
the patient safety objectives
European Stakeholder Model
Aligned to a Common vision to protect patients
E U R O P E A N M E D I C I N E S V E R I F I C A T I O N S Y S T E M 10
Protect patients
Secure the legitimate supply chain
Be proactive as market partners
Formed a stakeholder-governed model that is
Functioning
Harmonised
Cost-effective
Inter-operable
Established the European Medicines
Verification Organization (EMVO)
Andreas Walter, EMVO, General Manager
European Medicines Verification Organization (EMVO)
System management and governance by not-for-profit organisation
under supervision of relevant competent authority
E U R O P E A N M E D I C I N E S V E R I F I C A T I O N S Y S T E M 11
Governance Structure
Allows for Effective Management of Verification System
EMVO and National Organisations (NMVOs) cooperate on the basis of service level agreements
NATIONAL LEVEL• National Medicines Verification
Organisations (NMVO), e.g. in Germany: securPharm e.V.
• Governed by national stakeholders with supervision by competent authorities
EU LEVEL• Governance model includes
EU industry associations with supervision by EC
• Oversees EU Hub Blueprint template Service providers Service agreements
Basic Principles
Basic concept: “Point-of-Dispense Verification”
All verification activities are performed in national systems of the EU memberstates
Interoperability between the different national systems through European Hub
Data owned by party that generates it
Data of other parties cannot be accessed except:
For verification purposes
If specifically agreed between partners
Supervision by relevant competent authorities
For reimbursement / pharmacovigilance purposes
E U R O P E A N M E D I C I N E S V E R I F I C A T I O N S Y S T E M 12
Support for the GS1 Standards
E U R O P E A N M E D I C I N E S V E R I F I C A T I O N S Y S T E M 13
http://www.efpia.eu/uploads/Modules/Documents/efpia-gs1-shared-vision-090312_2.pdf
http://www.ifpma.org/wp-content/uploads/2016/03/Joint-Industry-Position-Paper-on-Serialization-and-Product-Verification-.pdf
Concept: Point of Dispense Verification
E U R O P E A N M E D I C I N E S V E R I F I C A T I O N S Y S T E M 14
Pan European ArchitectureDesigned for interoperability and efficiency
E U R O P E A N M E D I C I N E S V E R I F I C A T I O N S Y S T E M 15
German National
System
PharmacyWholesaler
Pharmaceutical
Manufacturer
Parallel
Distributor
National
System
National
System
National
System
National
System
National
System
European
Hub
E U R O P E A N M E D I C I N E S V E R I F I C A T I O N S Y S T E M 16
The National Blueprint System Approach
Interoperable, cost efficient, reduced complexity
National
System
PharmacyWholesaler
Pharmaceutical
Manufacturer
Parallel
Distributor
National Blueprint
System
National
System
National Blueprint
System
National Blueprint
System
National
System
European
Hub
Content
E U R O P E A N M E D I C I N E S V E R I F I C A T I O N S Y S T E M 17
Medicines verification in the EU: Overview
European Stakeholder Model → EMVO
Progress to date
EU Hub Progress to Date
E U R O P E A N M E D I C I N E S V E R I F I C A T I O N S Y S T E M 18
EU Hub built and operational
Companies testing data uploads to EU Hub
EU Hub connected to German securPharm system
Companies preparing to load data to EU Hub intended for
the German securPharm system
NMVO/NMVS Current Status
E U R O P E A N M E D I C I N E S V E R I F I C A T I O N S Y S T E M 19
NMVS Blueprint Template solution providers selected and frame contracts negotiated
Majority of countries prefer adopting the Blueprint Template
Working with national associations to form NMVOs and prepare to deploy national systems
15
14
22
0
31
11
810
16
24
6
27
132
8
4
3
26
19
17
8
12
30
9
32
2
5
29
22
7
11
5
23
2
1
Blueprint candidate
Small Country Blueprint
Blueprint open
Standalone system
No Information
Non EU Countries
EMVO Observations
Program Progress
Positive development in a few Countries
Most Countries aim for Supplier Contract in 2016
To be improved
Too many Countries not Aligned yet
Stakeholder Alignment in MOU and Statutes not complete in
several Countries (e.g. Pharmacies and Wholesalers not
integrated in NMVO set up)
Technical Work Stream not yet started in too many Countries
No further progress in favour of Blueprint
E U R O P E A N M E D I C I N E S V E R I F I C A T I O N S Y S T E M 20
NMVOs forming now
NMVOs selecting Blueprint vendor in 2016
Deploying 32 NMVS’s in advance of February 9, 2019
deadline
E U R O P E A N M E D I C I N E S V E R I F I C A T I O N S Y S T E M 21
Next steps…
EFPIA Brussels Office
Leopold Plaza Building
Rue du Trône 108
B-1050 Brussels - Belgium
Tel: +32 (0)2 626 25 55
www.efpia.eu
EFPIA Supply Chain Workgroup – Coding & Serialisation